Clinical Trial Update: Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating dual-target MSLN/FAP CAR-NK cells for malignant pleural and peritoneal mesothelioma; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Peritoneal Mesothelioma
• Malignant Pleural Mesothelioma

Drugs mentioned

• Dual-target MSLN/FAP CAR-NK cells

Snippet

Sponsor: Beijing Biotech | Conditions: Malignant Pleural Mesotheliomas | Phase 1, Phase 2 | Status: RECRUITING